Blend noteCJC-1295

CJC-1295, ipamorelin and sermorelin blend: composition and analysis

Composition note for the three-component 30 mg preparation: what each compound is, how the split is recorded, and how one certificate of analysis carries a separate purity and identity line for each.

Last reviewed: 2026-09-22
Reviewer: editorial review pending
Revision: 1
Sources: 11

Composition

The preparation is a single lyophilised powder containing three compounds, CJC-1295, ipamorelin and sermorelin, with a total peptide mass of 30 mg per vial. The mass of each component has not been confirmed, so no per-compound split is stated; the catalogue record carries the total quantity only until a split is verified against a certificate.

CJC-1295 is a name applied to two chemically distinct analogues of growth hormone-releasing hormone fragment 1-29. The form carrying the albumin-binding drug affinity complex is a 30-residue peptide recorded with CAS 446262-90-4, UNII 62RC32V9N7, PubChem CID 91971820, formula C165H269N47O46 and a molecular weight of 3647.2 g/mol; the form without it is the 29-residue tetrasubstituted GRF(1-29) amide, CAS 446036-97-1, PubChem CID 56841945, formula C152H252N44O42 and 3367.9 g/mol, for which no UNII exists ¹²³⁴. Which of the two is supplied is unconfirmed, and FDA treats them as different active moieties ⁴.

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue recorded with CAS 170851-70-4, UNII Y9M3S784Z6, PubChem CID 9831659, formula C38H49N9O5 and a molecular weight of 711.9 g/mol ⁵⁶⁷⁸.

Sermorelin is the synthetic 29-residue amide corresponding to the N-terminal fragment of human growth hormone-releasing hormone, sequence YADAIFTNSYRKVLGQLSARKLLQDIMSR, recorded with CAS 86168-78-7, UNII 89243S03TE, PubChem CID 16132413, formula C149H246N44O42S and a molecular weight of 3357.9 g/mol ⁹¹⁰¹¹.

Analytical characterisation

Each compound in a multi-component preparation is identified and quantified separately on the same certificate of analysis. The data model pairs one certificate with one compound and records, per compound: a chromatographic purity figure with the high-performance liquid chromatography method used, and a mass-spectrometric identity line giving the method, the expected and observed masses and whether identity was confirmed, together with the assayed mass and net peptide content. A three-component preparation therefore produces three such rows on one certificate, and neither a combined purity figure nor a combined mass is meaningful across the set.

Sermorelin and the two CJC-1295 forms differ in molecular weight by amounts a single intact-mass measurement can resolve, which is why identity is recorded per compound rather than for the preparation. No pharmacopoeial monograph, official reference standard or impurity specification exists for any CJC-1295-related substance, so no compendial specification can be quoted for that line ⁴.

Analytical data

Certificates of analysis, identity data and lot verification for the research material characterised on this page.

View analytical data · CJC-1295 / Ipamorelin / Sermorelin blend →

Component monographs

Identity, evidence and dated regulatory status for each compound are set out separately:

References

1.GSRS substance record CJC-1295, UNII 62RC32V9N7 (full view, retrieved through the GSRS API). FDA Global Substance Registration System, NCATS (2026). https://gsrs.ncats.nih.gov/api/v1/substances(62RC32V9N7)?view=full · accessed 2026-09-21
2.PubChem CID 91971820, CJC-1295 (retrieved through PUG REST: properties and synonyms). PubChem, National Center for Biotechnology Information (2026). https://pubchem.ncbi.nlm.nih.gov/compound/91971820 · accessed 2026-09-21
3.PubChem CID 56841945, 29-residue tetrasubstituted GRF(1-29) amide (retrieved through PUG REST identity search, properties and synonyms). PubChem, National Center for Biotechnology Information (2026). https://pubchem.ncbi.nlm.nih.gov/compound/56841945 · accessed 2026-09-21
4.Mai Tu, Edna Albuquerque, Andrea Benedict, Marianne San Antonio, Suhail Kasim, Ashlee Mattingly, Tracy Rupp. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, December 4, 2024: Evaluation of five CJC-1295-related bulk drug substances. U.S. Food and Drug Administration (2024). https://www.fda.gov/media/183819/download · accessed 2026-09-21
5.IPAMORELIN substance record (UNII Y9M3S784Z6), Global Substance Registration System. FDA / NCATS Global Substance Registration System (2026). https://gsrs.ncats.nih.gov/api/v1/substances(Y9M3S784Z6)?view=full · accessed 2026-09-21
6.Ipamorelin, CID 9831659 - properties, synonyms and structure. PubChem, National Center for Biotechnology Information (2026). https://pubchem.ncbi.nlm.nih.gov/compound/9831659 · accessed 2026-09-21
7.IPAMORELIN, ChEMBL molecule CHEMBL58547. European Bioinformatics Institute (2026). https://www.ebi.ac.uk/chembl/api/data/molecule/CHEMBL58547.json · accessed 2026-09-21
8.FDA Briefing Document, Pharmacy Compounding Advisory Committee: Evaluation of Ipamorelin-related Bulk Drug Substances for Inclusion on the 503A Bulk Drug Substances List. US Food and Drug Administration (2024). https://www.fda.gov/media/182088/download · accessed 2026-09-21
9.SERMORELIN (UNII 89243S03TE) - Global Substance Registration System. FDA / NCATS GSRS (2026). https://gsrs.ncats.nih.gov/api/v1/substances/search?q=89243S03TE · accessed 2026-09-21
10.Sermorelin (CID 16132413). PubChem, NCBI/NLM (2026). https://pubchem.ncbi.nlm.nih.gov/compound/16132413 · accessed 2026-09-21
11.Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs (1999). doi:10.2165/00063030-199912020-00007 PMID 18031173 · accessed 2026-09-21